Royce & Associates LP Has $5,519,000 Stake in Inogen, Inc (INGN)

Royce & Associates LP continued to hold its stake in shares of Inogen, Inc (NASDAQ:INGN) during the first quarter, Holdings Channel reports. The fund owned 71,155 shares of the medical technology company’s stock at the end of the first quarter. Royce & Associates LP’s holdings in Inogen were worth $5,519,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of INGN. TIAA CREF Investment Management LLC increased its stake in shares of Inogen by 4.7% in the first quarter. TIAA CREF Investment Management LLC now owns 101,458 shares of the medical technology company’s stock worth $7,869,000 after buying an additional 4,600 shares during the last quarter. Teachers Advisors LLC increased its stake in shares of Inogen by 2.8% in the first quarter. Teachers Advisors LLC now owns 27,790 shares of the medical technology company’s stock worth $2,155,000 after buying an additional 749 shares during the last quarter. FMR LLC increased its stake in shares of Inogen by 56.2% in the first quarter. FMR LLC now owns 324,200 shares of the medical technology company’s stock worth $25,145,000 after buying an additional 116,600 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of Inogen by 4.3% in the first quarter. Principal Financial Group Inc. now owns 135,356 shares of the medical technology company’s stock worth $10,498,000 after buying an additional 5,613 shares during the last quarter. Finally, Credit Agricole S A increased its stake in shares of Inogen by 20.0% in the first quarter. Credit Agricole S A now owns 132,000 shares of the medical technology company’s stock worth $10,238,000 after buying an additional 22,000 shares during the last quarter.

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Inogen, Inc (NASDAQ:INGN) traded up 1.1090% on Tuesday, hitting $94.8099. 56,781 shares of the company were exchanged. Inogen, Inc has a 52 week low of $44.26 and a 52 week high of $95.43. The company has a market capitalization of $1.95 billion, a P/E ratio of 84.8031 and a beta of 1.04. The firm’s 50 day moving average is $87.09 and its 200 day moving average is $74.58.

Inogen (NASDAQ:INGN) last released its quarterly earnings results on Tuesday, May 9th. The medical technology company reported $0.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.15. The company had revenue of $52.50 million for the quarter, compared to analyst estimates of $49.06 million. Inogen had a net margin of 9.32% and a return on equity of 11.67%. The firm’s revenue was up 22.1% on a year-over-year basis. During the same quarter last year, the business earned $0.12 earnings per share. On average, equities research analysts forecast that Inogen, Inc will post $1.04 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Royce & Associates LP Has $5,519,000 Stake in Inogen, Inc (INGN)” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/2655561/royce-associates-lp-has-5519000-stake-in-inogen-inc-ingn.html.

A number of brokerages have recently issued reports on INGN. Needham & Company LLC boosted their price objective on shares of Inogen from $96.00 to $108.00 and gave the company a “strong-buy” rating in a research report on Friday, June 9th. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “strong-buy” rating and set a $94.00 target price on the stock in a research note on Monday, May 15th. Stifel Nicolaus lifted their target price on shares of Inogen from $65.00 to $75.00 and gave the company a “hold” rating in a research note on Wednesday, May 10th. Sidoti began coverage on shares of Inogen in a research note on Tuesday, April 18th. They set a “neutral” rating and a $79.00 target price on the stock. Finally, TheStreet upgraded shares of Inogen from a “c” rating to a “b-” rating in a research note on Tuesday, February 28th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $86.80.

In related news, EVP Matt Scribner sold 2,500 shares of the firm’s stock in a transaction on Monday, April 17th. The shares were sold at an average price of $75.28, for a total transaction of $188,200.00. Following the sale, the executive vice president now owns 4,064 shares in the company, valued at $305,937.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Scott Wilkinson sold 23,437 shares of the firm’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $88.06, for a total transaction of $2,063,862.22. Following the sale, the insider now owns 54,088 shares in the company, valued at approximately $4,762,989.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 83,848 shares of company stock worth $7,283,201. 5.31% of the stock is owned by company insiders.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:INGN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen, Inc (NASDAQ:INGN).

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.